
Ginkgo inks $144M deal with Merck to engineer enzymes to improve ingredient manufacturing
While Merck has not been averse to partnering with smaller companies and the odd startup, its latest partnership sees it linking arms with Ginkgo Bioworks to help boost active pharmaceutical ingredient production through the use of enzymes.
The partnership will have Ginkgo develop a strain of biocatalysts that can be used in chemical synthesis for the production of APIs. Ginkgo can earn upfront R&D fees and milestone payments, as well as commercial payments which have the potential to rake in up to $144 million for the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.